Navigation Links
Vasogen Announces Second Quarter 2009 Results
Date:7/14/2009

revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2008, as well as in our other public filings, including our Management's Discussion and Analysis for the period ended May 31, 2009. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                 Summary financial tables are provided below.


    VASOGEN INC.
    (A DEVELOPMENT STAGE COMPANY)
    Interim Consolidated Balance Sheets
    
'/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ... Companies"  to their offering.       ... a challenge in management. With nearly 8 ... seven major markets of the world and ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) ... Market by Products, by Testing services - Global Forecast ... The global animal genetics market is estimated to be ... a CAGR of 8-9% during the forecast period of ... driven by increasing animal protein consumption, increasing adoption of ...
(Date:5/28/2015)... 28, 2015 Natera, Inc., a leader ... published in Ultrasound in Obstetrics & Gynecology ... non-invasive prenatal test (NIPT) can identify a complete ... A study based upon data collected in ... in about 1 in 1,000 pregnancies, although other ...
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... JOSEPH, Mich., Feb. 5 GeneGo, Inc., the ... has extended their,licensing agreement with GeneGo and have ... Bioinformatics, R&D and clinical studies,with global access to ... for functional analysis of biological OMICs data,featuring a ...
... Forest Laboratories, Inc.,(NYSE: FRX ) ... III study of,memantine HCl (currently marketed as ... novel once-daily formulation. The study evaluated,the efficacy, ... 28 mg,memantine extended-release, once-daily formulation compared to ...
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a biotechnology Company ... targeting the chronic inflammation,underlying cardiovascular and neurological disease, ... present a Company Overview at BIO,CEO & Investor ... at 11:00,a.m. (ET) on Tuesday, February 12, 2008. ...
Cached Biology Technology:GSK Extends GeneGo License and Adds New Products 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 2Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 3Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation 4Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 2Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Immunogenetics experts at The Children,s Hospital of Philadelphia ... characterize the genes that encode HLA molecules. The ... technology to type human leukocyte antigens (HLAs)--complex, highly ... to immune function. The new test may ...
... will be the subject of a symposium on Saturday, February 15, ... Advancement of Science in Chicago. The session, which features two ... Martin Chalfie, will take place 10:00-11:30 a.m. CST in Grand Ballroom ... the first 2014 winner of the Golden Goose Award ...
... aware of the health benefits of dietary fiber. But what ... Research at the University of Michigan Medical School, the University ... Sweden, has begun to uncover how our gut bacteria metabolize ... Trillions of bacteria live in human intestines - there are ...
Cached Biology News:CHOP introduces HLA typing by next-generation sequencing to its clinical services 2CHOP introduces HLA typing by next-generation sequencing to its clinical services 3U-M scientists & colleagues investigate the fiber of our being 2
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
...
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
Biology Products: